WO2003069348A3 - USE OF MIP-3α AND ITS RECEPTOR TO TREAT ARTHRITIS - Google Patents

USE OF MIP-3α AND ITS RECEPTOR TO TREAT ARTHRITIS Download PDF

Info

Publication number
WO2003069348A3
WO2003069348A3 PCT/EP2003/001506 EP0301506W WO03069348A3 WO 2003069348 A3 WO2003069348 A3 WO 2003069348A3 EP 0301506 W EP0301506 W EP 0301506W WO 03069348 A3 WO03069348 A3 WO 03069348A3
Authority
WO
WIPO (PCT)
Prior art keywords
mip
osteoarthritis
receptor
treat
chemokine
Prior art date
Application number
PCT/EP2003/001506
Other languages
French (fr)
Other versions
WO2003069348A2 (en
Inventor
Chandrika Saidapet Kumar
Mark Aron Labow
Brian Jude Latario
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Chandrika Saidapet Kumar
Mark Aron Labow
Brian Jude Latario
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh, Chandrika Saidapet Kumar, Mark Aron Labow, Brian Jude Latario filed Critical Novartis Ag
Priority to AU2003208858A priority Critical patent/AU2003208858A1/en
Publication of WO2003069348A2 publication Critical patent/WO2003069348A2/en
Publication of WO2003069348A3 publication Critical patent/WO2003069348A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to novel uses for the chemokine MIP-3α and its receptor CCR6 to treat and diagnose osteoarthritis. In particular, MIP-3α is shown to be expressed in cartilage tissue and chondrocytes derived from individuals having osteoarthritis, whereas normally the chemokine is not expressed in such cells or tissues. These findings indicate that both the MIP-3α chemokine and the CCR6 receptor are useful targets, e.g., for the development of therapeutics to treat, ameliorate and/or modulate conditions such as osteoarthritis. Accordingly, the invention provides screening methods for identifying candidate compounds that modulate MIP-3α binding to its receptor and may therefore be used to treat osteoarthritis. Therapeutic methods and pharmaceutical compositions that inhibit MIP-3α expression or activity or, alternatively, inhibit CCR6 expression or activity are also provided. Finally, the invention also provides diagnostic and prognostic methods for identifying individuals having osteoarthritis by detecting MIP-3α expression.
PCT/EP2003/001506 2002-02-15 2003-02-14 USE OF MIP-3α AND ITS RECEPTOR TO TREAT ARTHRITIS WO2003069348A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003208858A AU2003208858A1 (en) 2002-02-15 2003-02-14 USE OF MIP-3Alpha AND ITS RECEPTOR TO TREAT ARTHRITIS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35758802P 2002-02-15 2002-02-15
US60/357,588 2002-02-15

Publications (2)

Publication Number Publication Date
WO2003069348A2 WO2003069348A2 (en) 2003-08-21
WO2003069348A3 true WO2003069348A3 (en) 2004-07-29

Family

ID=27734758

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/001506 WO2003069348A2 (en) 2002-02-15 2003-02-14 USE OF MIP-3α AND ITS RECEPTOR TO TREAT ARTHRITIS

Country Status (2)

Country Link
AU (1) AU2003208858A1 (en)
WO (1) WO2003069348A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009096716A (en) * 2006-01-19 2009-05-07 Eisai R & D Management Co Ltd Treatment of autoimmune disease by anti-ccl20 antibody
WO2007130636A2 (en) * 2006-05-03 2007-11-15 Geisinger Clinic Methods for diagnosing and predicting non-alcoholic steatohepatitis (nash)
US20130316338A1 (en) * 2010-06-29 2013-11-28 The United States Government As Represented By The Department Of Veterans Affairs CCR6 As A Biomarker of Alzheimer's Disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BORZ R M ET AL: "Flow cytometric analysis of intracellular chemokines in chondrocytes in vivo: constitutive expression and enhancement in osteoarthritis and rheumatoid arthritis", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 455, no. 3, 23 July 1999 (1999-07-23), pages 238 - 242, XP004259997, ISSN: 0014-5793 *
CHABAUD M ET AL: "Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein-3alpha production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 15 NOV 2001, vol. 167, no. 10, 15 November 2001 (2001-11-15), pages 6015 - 6020, XP002249676, ISSN: 0022-1767 *
LISIGNOLI G ET AL: "Chemokine expression by subchondral bone marrow stromal cells isolated from osteoarthritis (OA) and rheumatoid arthritis (RA) patients.", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 116, no. 2, May 1999 (1999-05-01), pages 371 - 378, XP002249675, ISSN: 0009-9104 *

Also Published As

Publication number Publication date
AU2003208858A8 (en) 2003-09-04
AU2003208858A1 (en) 2003-09-04
WO2003069348A2 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
Franzen et al. Senescence‐associated DNA methylation is stochastically acquired in subpopulations of mesenchymal stem cells
Lane et al. Frizzled‐related protein variants are risk factors for hip osteoarthritis
WO2005084109A3 (en) Cancer specific gene mh15
WO2005048926A3 (en) Methods for treating pain
DE69934688D1 (en) BY MECHANICAL STRESS INDUCED GENES, THEIR EXPRESSION PRODUCTS AND THEIR USE.
WO2002085285A3 (en) Methods and reagents for regulating bone and cartilage formation
Valentini et al. Analysis of the machinery and intermediates of the 5hmC-mediated DNA demethylation pathway in aging on samples from the MARK-AGE Study
EP3552607A3 (en) Imidazopyrazine syk inhibitors
NO20064212L (en) Piperidinyl which targets compounds that selectively bind integrins
Golovine et al. Cadmium down-regulates expression of XIAP at the post-transcriptional level in prostate cancer cells through an NF-κB-independent, proteasome-mediated mechanism
Blackburn et al. RNA sequencing identifies a novel USP9X‐USP6 promoter swap gene fusion in a primary aneurysmal bone cyst
TR200003159T2 (en) Antipicornaviral compounds, their preparation and uses
Yang et al. Lnc RNA ZFAS1 regulates the proliferation, apoptosis, inflammatory response and autophagy of fibroblast-like synoviocytes via miR-2682-5p/ADAMTS9 axis in rheumatoid arthritis
Wang et al. Activation of mitochondrial pathway is crucial for tumor selective induction of apoptosis by LAQ824
MX2007005054A (en) Vwfa and/or ant_ig domain containing proteins.
WO2003069348A3 (en) USE OF MIP-3α AND ITS RECEPTOR TO TREAT ARTHRITIS
WO1999051186A3 (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
Kehayova et al. Mediation of the Same Epigenetic and Transcriptional Effect by Independent Osteoarthritis Risk–Conferring Alleles on a Shared Target Gene, COLGALT2
WO2003105773A3 (en) Activating mutations of platelet derived growth factor receptor alpha (pdgfra) as diagnostic markers and therapeutic targets:
Sasaki et al. Isolation and characterization of a novel gene, hRFI, preferentially expressed in esophageal cancer
Rodríguez Ruiz et al. Mutation in the CCAL1 locus accounts for bidirectional process of human subchondral bone turnover and cartilage mineralization
DE60221115D1 (en) COMPOSITIONS AND METHODS FOR USE OF FIBRONECTIN FRAGMENTS IN CANCER DIAGNOSIS
WO2003068268A3 (en) Treatment, diagnosis and imaging of disease
Li et al. Validation of fluorescence in situ hybridization testing of USP6 gene rearrangement for diagnosis of primary aneurysmal bone cyst
WO2005106489A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 5 (ccr5)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LT LU LV MA MD MK MN MX NO NZ OM PH PL PT RO RU SC SE SG SK TJ TM TN TR TT UA US UZ VC VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP